Joinn Laboratories(China)Co.,Ltd. (HKG:6127)

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015
Non-clinical studies services	1.92B	-	-	-						-
Sales of research models	317.75M	-	-	-						-
Clinical trial and related services	99.94M	-	-	-						-
Inter-Segment Revenue	-317.71M	-	-	-						-3.72M
Technical Service Income	-	-	-	-						193.73M
Technical Service Income Growth	-	-	-	-						12.57%
Experimental Animal Production and Sales	-	-	-	-						12.15M
Experimental Animal Production and Sales Growth	-	-	-	-						159.04%
Total	2.02B	-	-	-						202.15M
Total Growth	-	-	-	-						14.35%

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015
The PRC	1.58B	-	-	-						-
Overseas	438.95M	-	-	-						15.45M
Overseas Growth	-	-	-	-						347.03%
East China	-	-	-	-						70.32M
East China Growth	-	-	-	-						35.58%
North China	-	-	-	-						71.69M
North China Growth	-	-	-	-						25.19%
South China	-	-	-	-						20.67M
South China Growth	-	-	-	-						-27.41%
Northeast China	-	-	-	-						8.25M
Northeast China Growth	-	-	-	-						9.99%
Central China	-	-	-	-						5.74M
Central China Growth	-	-	-	-						-68.91%
West China	-	-	-	-						10.02M
West China Growth	-	-	-	-						2.86%
Total	2.02B	-	-	-						202.15M
Total Growth	-	-	-	-						14.35%

Source: S&P Global Market Intelligence.